- 93 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
A 48-year-old man experienced progression of colorectal adenocarcinoma, due to acquired resistance during treatment with bevacizumab, capecitabine, cetuximab, oxaliplatin, pertuzumab, trastuzumab and trastuzumab-emtansine [trastuzumab-DM1]. Additionally, he developed diarrhoea following an off-label treatment with trastuzumab-emtansine [routes and dosages not stated].
The man was diagnosed with colorectal adenocarcinoma with serum carcinoembryonic antigen (CEA) level of 39.5 ng/mL at the time of diagnosis. Molecular analysis demonstrated a KRAS, NRAS, and BRAF wild-type tumour with intact mismatch repair proteins. The gene sequencing of the primary tumour showed ERBB2 (HER2) and MYC amplification and a TP53 R175H and APC R1386* mutation. He was started on first line therapy with...
- Parikh A, et al. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network 15: 3-8, No. 1, Jan 2017. Available from: URL: https://www.ncbi.nlm.nih.gov/pubmed/28040715 - USACrossRefPubMedPubMedCentralGoogle Scholar